Pfizer's Prevenar wins Japanese approval; Judge rules unvaccinated students must stay home during illness;

> Pfizer's ($PFE) Prevenar 13 has scored approval in Japan for use in adults aged 65 and older. Report

> A New York judge has upheld the policy barring unvaccinated students from public schools when another student has a vaccine-preventable disease. Report (sub. req.)

> GlaxoSmithKline's ($GSK) vaccine plant in Texas is about a year away from completion. More

> The GAVI Alliance has approved a new strategic framework to reach an additional 300 million children with vaccines. Release

> Madison Vaccines is expanding its Phase II trial for prostate cancer DNA vaccine MVI-816. Release

Suggested Articles

GSK's Shingrix has generated blockbuster sales early in the launch, but there's a lot of remaining opportunity, an exec said at JPM.

Quickly after Merck's world-first Ebola vaccine approval in Europe, U.S. authorities licensed the shot.

In an effort to stop an Ebola outbreak that has claimed 2,200 lives at the Rwanda border, J&J is shipping 200,000 doses of its vaccine to the country.